Ultime notizie per Earth Life Sciences (OTC:CLTS) Azioni

Earth Life Sciences Inc offers Artificial Intelligence (AI)-driven mileage-based loyalty system for public transportation. The Miltean's AI platform enables an increase of ridership, decongestion analysis, interruption of service compensation, congestion management, prediction and analysis of ridership usage patterns. The firm caters to public traffic management systems and team up relationships between private and public enterprise.

EARTH LIFE SCIENCES by Earth Life Sciences Inc.

Earth Life Sciences Inc

<p><strong>Cathay General</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CATY#NASDAQ">CATY</a>) is set to give its latest quarterly earnings report on Monday, 2024-10-21. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Cathay General will report an <strong>earnings per share</strong> (EPS) of $0.95. </p>
<p>The announcement from Cathay General is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Performance in Previous Earnings</h3>
<p>During the last quarter, the company reported an EPS beat by $0.02, leading to a 0.65% increase in the share price on the subsequent day.</p>
<p>Here's a look at Cathay General's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.94</td>
<td>0.98</td>
<td>1.06</td>
<td>1.10</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.96</td>
<td>0.98</td>
<td>1.25</td>
<td>1.13</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>1.0%</td>
<td>-5.0%</td>
<td>-2.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729275799_0.png" alt="eps graph" /></p>
<h3>Market Performance of Cathay General's Stock</h3>
<p>Shares of Cathay General were trading at $46.61 as of October 17. Over the last 52-week period, shares are up 38.83%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/CATY/earnings"><strong>To track all earnings releases for Cathay General visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings

CATY

A Preview Of Cathay General's Earnings

<p>Medpace Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDP#NASDAQ">MEDP</a>) is gearing up to announce its quarterly earnings on Monday, 2024-10-21. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Medpace Hldgs will report an <strong>earnings per share</strong> (EPS) of $2.80.</p>
<p>The market awaits Medpace Hldgs's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Historical Earnings Performance</h3>
<p>During the last quarter, the company reported an EPS beat by $0.21, leading to a 18.27% drop in the share price on the subsequent day.</p>
<p>Here's a look at Medpace Hldgs's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>2.54</td>
<td>2.46</td>
<td>2.22</td>
<td>2.04</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>2.75</td>
<td>3.20</td>
<td>2.46</td>
<td>2.22</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-18.0%</td>
<td>8.0%</td>
<td>12.0%</td>
<td>20.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729275745_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Medpace Hldgs were trading at $342.89 as of October 17. Over the last 52-week period, shares are up 55.67%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analysts' Take on Medpace Hldgs</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Medpace Hldgs.</p>
<p>Analysts have provided Medpace Hldgs with 10 ratings, resulting in a consensus rating of Neutral. The average one-year price target stands at $395.6, suggesting a potential 15.37% upside.</p>
<h3>Comparing Ratings Among Industry Peers</h3>
<p>In this analysis, we delve into the analyst ratings and average 1-year price targets of Bio-Techne, Charles River and Bio-Rad Laboratories, three key industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>For Bio-Techne, analysts project an Buy trajectory, with an average 1-year price target of $82.33, indicating a potential 75.99% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Charles River, with an average 1-year price target of $203.75, suggesting a potential 40.58% downside.</li>
<li>As per analysts' assessments, Bio-Rad Laboratories is favoring an Neutral trajectory, with an average 1-year price target of $378.4, suggesting a potential 10.36% upside.</li>
</ul>
<h3>Snapshot: Peer Analysis</h3>
<p>The peer analysis summary presents essential metrics for Bio-Techne, Charles River and Bio-Rad Laboratories, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medpace Hldgs</td>
<td>Neutral</td>
<td>14.59%</td>
<td>$153.84M</td>
<td>12.31%</td>
</tr>
<tr>
<td>Bio-Techne</td>
<td>Buy</td>
<td>1.59%</td>
<td>$203.35M</td>
<td>1.99%</td>
</tr>
<tr>
<td>Charles River</td>
<td>Neutral</td>
<td>-3.19%</td>
<td>$353.71M</td>
<td>2.44%</td>
</tr>
<tr>
<td>Bio-Rad Laboratories</td>
<td>Neutral</td>
<td>-6.26%</td>
<td>$355.12M</td>
<td>-27.36%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Medpace Hldgs ranks in the middle among its peers for revenue growth, with positive growth compared to some peers. It is at the top for gross profit, indicating strong profitability. However, its return on equity is lower than some peers, suggesting room for improvement in utilizing shareholder equity effectively. Overall, Medpace Hldgs shows a balanced performance compared to its peers in these key financial metrics.</p>
<h3>Delving into Medpace Hldgs's Background</h3>
<p>Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical-device firms. It also offers ancillary services such as bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has over 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati and its operations are principally based in the us, but it also operates in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.</p>
<h3>Understanding the Numbers: Medpace Hldgs's Finances</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Medpace Hldgs displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately <strong>14.59%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Medpace Hldgs's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>16.73%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>12.31%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>4.76%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> Medpace Hldgs's debt-to-equity ratio is below the industry average at <strong>0.17</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<p><a href="https://www.benzinga.com/quote/MEDP/earnings"><strong>To track all earnings releases for Medpace Hldgs visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


MEDP

Insights Ahead: Medpace Hldgs's Quarterly Earnings

<p>Cadence Bank (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CADE#NYSE">CADE</a>) will release its quarterly earnings report on Monday, 2024-10-21. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Cadence Bank to report an <strong>earnings per share</strong> (EPS) of $0.64.</p>
<p>Anticipation surrounds Cadence Bank's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Earnings Track Record</h3>
<p>Last quarter the company beat EPS by $0.08, which was followed by a 3.93% increase in the share price the next day.</p>
<p>Here's a look at Cadence Bank's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.61</td>
<td>0.55</td>
<td>0.53</td>
<td>0.57</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.69</td>
<td>0.62</td>
<td>0.40</td>
<td>0.56</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>4.0%</td>
<td>4.0%</td>
<td>-6.0%</td>
<td>5.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729275738_0.png" alt="eps graph" /></p>
<h3>Performance of Cadence Bank Shares</h3>
<p>Shares of Cadence Bank were trading at $33.5 as of October 17. Over the last 52-week period, shares are up 68.51%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/CADE/earnings"><strong>To track all earnings releases for Cadence Bank visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


CADE

A Peek at Cadence Bank's Future Earnings

<p><strong>BOK Financial</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOKF#NASDAQ">BOKF</a>) is set to give its latest quarterly earnings report on Monday, 2024-10-21. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that BOK Financial will report an <strong>earnings per share</strong> (EPS) of $1.98. </p>
<p>The market awaits BOK Financial's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Earnings History Snapshot</h3>
<p>In the previous earnings release, the company missed EPS by $0.32, leading to a 0.74% drop in the share price the following trading session.</p>
<p>Here's a look at BOK Financial's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>2.34</td>
<td>1.73</td>
<td>1.75</td>
<td>2.09</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>2.02</td>
<td>1.91</td>
<td>1.76</td>
<td>2.04</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-1.0%</td>
<td>-3.0%</td>
<td>3.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729275725_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of BOK Financial were trading at $114.66 as of October 17. Over the last 52-week period, shares are up 57.6%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/BOKF/earnings"><strong>To track all earnings releases for BOK Financial visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


BOKF

BOK Financial's Earnings Outlook

<p>Enterprise Finl Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EFSC#NASDAQ">EFSC</a>) will release its quarterly earnings report on Monday, 2024-10-21. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Enterprise Finl Servs to report an <strong>earnings per share</strong> (EPS) of $1.14.</p>
<p>The market awaits Enterprise Finl Servs's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Historical Earnings Performance</h3>
<p>The company's EPS beat by $0.15 in the last quarter, leading to a 12.37% increase in the share price on the following day.</p>
<p>Here's a look at Enterprise Finl Servs's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.06</td>
<td>1.11</td>
<td>1.19</td>
<td>1.24</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.21</td>
<td>1.07</td>
<td>1.21</td>
<td>1.17</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>12.0%</td>
<td>-1.0%</td>
<td>-4.0%</td>
<td>-6.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729275717_0.png" alt="eps graph" /></p>
<h3>Enterprise Finl Servs Share Price Analysis</h3>
<p>Shares of Enterprise Finl Servs were trading at $53.85 as of October 17. Over the last 52-week period, shares are up 48.98%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/EFSC/earnings"><strong>To track all earnings releases for Enterprise Finl Servs visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


EFSC

Enterprise Finl Servs's Earnings Outlook

<p><strong>Alexandria Real Estate</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARE#NYSE">ARE</a>) is set to give its latest quarterly earnings report on Monday, 2024-10-21. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Alexandria Real Estate will report an <strong>earnings per share</strong> (EPS) of $2.37. </p>
<p>Alexandria Real Estate bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Performance in Previous Earnings</h3>
<p>The company's EPS beat by $0.02 in the last quarter, leading to a 3.52% drop in the share price on the following day.</p>
<p>Here's a look at Alexandria Real Estate's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>2.34</td>
<td>2.32</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>2.36</td>
<td>2.35</td>
<td>2.28</td>
<td>2.26</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-4.0%</td>
<td>1.0%</td>
<td>-4.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>
</p>
<h3>Tracking Alexandria Real Estate's Stock Performance</h3>
<p>Shares of Alexandria Real Estate were trading at $121.25 as of October 17. Over the last 52-week period, shares are up 29.01%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Insights Shared by Analysts on Alexandria Real Estate</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Alexandria Real Estate.</p>
<p>The consensus rating for Alexandria Real Estate is Neutral, based on 8 analyst ratings. With an average one-year price target of $128.88, there's a potential 6.29% upside.</p>
<h3>Peer Ratings Overview</h3>
<p>This comparison focuses on the analyst ratings and average 1-year price targets of Ventas, Healthpeak Properties and Omega Healthcare Invts, three major players in the industry, shedding light on their relative performance expectations and market positioning.</p>
<ul>
<li>As per analysts' assessments, Ventas is favoring an Outperform trajectory, with an average 1-year price target of $65.88, suggesting a potential 45.67% downside.</li>
<li>The consensus outlook from analysts is an Outperform trajectory for Healthpeak Properties, with an average 1-year price target of $24.29, indicating a potential 79.97% downside.</li>
<li>For Omega Healthcare Invts, analysts project an Neutral trajectory, with an average 1-year price target of $42.2, indicating a potential 65.2% downside.</li>
</ul>
<h3>Summary of Peers Analysis</h3>
<p>The peer analysis summary outlines pivotal metrics for Ventas, Healthpeak Properties and Omega Healthcare Invts, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alexandria Real Estate</td>
<td>Neutral</td>
<td>7.40%</td>
<td>$549.48M</td>
<td>0.23%</td>
</tr>
<tr>
<td>Ventas</td>
<td>Outperform</td>
<td>8.55%</td>
<td>$519.18M</td>
<td>0.20%</td>
</tr>
<tr>
<td>Healthpeak Properties</td>
<td>Outperform</td>
<td>27.31%</td>
<td>$413.85M</td>
<td>1.65%</td>
</tr>
<tr>
<td>Omega Healthcare Invts</td>
<td>Neutral</td>
<td>1.02%</td>
<td>$249.00M</td>
<td>3.15%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Alexandria Real Estate ranks in the middle for revenue growth among its peers. It is at the bottom for gross profit and return on equity.</p>
<h3>All You Need to Know About Alexandria Real Estate</h3>
<p>Alexandria Real Estate Equities Inc is an urban office real estate investment trust (REIT). It is engaged in the business of providing space for lease to life science, agtech, and technology tenants. The company has established a significant market presence in key locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. Alexandria has a longstanding and proven track record of developing Class A properties clustered in urban life science, agtech, and technology campuses that provide tenants with highly dynamic and collaborative environments. Alexandria also provides strategic capital to transformative life science, agtech, and technology companies through venture capital platform.</p>
<h3>Financial Insights: Alexandria Real Estate</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Alexandria Real Estate's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>7.4%</strong> as of 30 June, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Real Estate sector.</p>
<p><strong>Net Margin:</strong> Alexandria Real Estate's net margin excels beyond industry benchmarks, reaching <strong>5.6%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Alexandria Real Estate's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>0.23%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Alexandria Real Estate's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>0.11%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.7</strong>.</p>
<p><a href="https://www.benzinga.com/quote/ARE/earnings"><strong>To track all earnings releases for Alexandria Real Estate visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings Outlook For Alexandria Real Estate

<p><strong>Guaranty Bancshares</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNTY#NYSE">GNTY</a>) is set to give its latest quarterly earnings report on Monday, 2024-10-21. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Guaranty Bancshares will report an <strong>earnings per share</strong> (EPS) of $0.60. </p>
<p>Investors in Guaranty Bancshares are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Earnings History Snapshot</h3>
<p>The company's EPS beat by $0.11 in the last quarter, leading to a 4.17% increase in the share price on the following day.</p>
<p>Here's a look at Guaranty Bancshares's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.54</td>
<td>0.51</td>
<td>0.47</td>
<td>0.55</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.65</td>
<td>0.58</td>
<td>0.51</td>
<td>0.54</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>4.0%</td>
<td>-4.0%</td>
<td>-0.0%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729275690_0.png" alt="eps graph" /></p>
<h3>Guaranty Bancshares Share Price Analysis</h3>
<p>Shares of Guaranty Bancshares were trading at $35.58 as of October 17. Over the last 52-week period, shares are up 29.53%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/GNTY/earnings"><strong>To track all earnings releases for Guaranty Bancshares visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


GNTY

Insights Ahead: Guaranty Bancshares's Quarterly Earnings

<p><a href="https://www.globenewswire.com/Tracker?data=J-vVffmoAvzJ5hT9V43152UijIiLA8G9jHrvYBFh90Z2CMB24fG2fE1DEvkYxJXY1gjsz3FatOl4f-MJEeQlxhi5YpMDUBp0AFconWEyHC_ekGmRbo6M_ovwuIcKxIKxMrbmDd4fmuoVtIHcsMjZmF9WGZygSsYFKYuktAPFClGXVkK7ypzGwTvJlgpjQWSQqRqdi79v1QsrZxb4yP5nVbw8WoCDTR7djZ1jcf2dOr0=">CVRx, Inc</a>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVRX#NASDAQ">CVRX</a>) ("CVRx"), a commercial-stage medical device company, announced today&nbsp;that the American Medical Association (AMA) CPT&#xAE; Editorial Panel has accepted new Current Procedural Terminology (CPT) Category I codes for baroreflex activation therapy ("Barostim") to treat the symptoms of heart failure.</p>
<p>In response to the increased utilization of Barostim therapy and the strong evidence supporting its clinical outcomes, the AMA CPT Editorial Panel accepted the application for Category I CPT codes. This decision will help further facilitate reimbursement for healthcare providers performing the Barostim procedure and enable broader patient access. This effort was led by the Society for Vascular Surgery (SVS) and supported by the American College of Cardiology (ACC) and others. These codes are expected to be implemented on January 1, 2026. In the interim, U.S. hospitals and physicians performing Barostim procedures should continue to utilize the existing Category III codes.</p>


Biotech

News

General

CVRX

CVRx Announces New Current Procedural Terminology Category I Codes For Barostim To Treat The Symptoms Of Heart Failure

<p><strong>KKR Real Estate Finance</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KREF#NYSE">KREF</a>) is set to give its latest quarterly earnings report on Monday, 2024-10-21. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that KKR Real Estate Finance will report an <strong>earnings per share</strong> (EPS) of $0.34. </p>
<p>Investors in KKR Real Estate Finance are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Performance in Previous Earnings</h3>
<p>In the previous earnings release, the company beat EPS by $0.09, leading to a 14.57% increase in the share price the following trading session.</p>
<p>Here's a look at KKR Real Estate Finance's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-1.66</td>
<td>0.34</td>
<td>0.11</td>
<td>0.22</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-1.57</td>
<td>0.39</td>
<td>-0.37</td>
<td>0.25</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>15.0%</td>
<td>-2.0%</td>
<td>-14.000000000000002%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729275683_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of KKR Real Estate Finance were trading at $12.0 as of October 17. Over the last 52-week period, shares are up 19.38%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/KREF/earnings"><strong>To track all earnings releases for KKR Real Estate Finance visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


KREF

A Preview Of KKR Real Estate Finance's Earnings

<p>Cathay General (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CATY#NASDAQ">CATY</a>) is gearing up to announce its quarterly earnings on Monday, 2024-10-21. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Cathay General will report an <strong>earnings per share</strong> (EPS) of $0.95.</p>
<p>The announcement from Cathay General is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Earnings History Snapshot</h3>
<p>The company's EPS beat by $0.02 in the last quarter, leading to a 0.65% increase in the share price on the following day.</p>
<p>Here's a look at Cathay General's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.94</td>
<td>0.98</td>
<td>1.06</td>
<td>1.10</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.96</td>
<td>0.98</td>
<td>1.25</td>
<td>1.13</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>1.0%</td>
<td>-5.0%</td>
<td>-2.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729275675_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Cathay General were trading at $46.61 as of October 17. Over the last 52-week period, shares are up 38.83%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/CATY/earnings"><strong>To track all earnings releases for Cathay General visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings Preview For Cathay General

<p>Canaccord Genuity  analyst Brian McNamara   maintains Lifetime Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCUT#NASDAQ">LCUT</a>) with a Buy and lowers the price target from $10 to $9.</p>


Price Target

Analyst Ratings

LCUT

Canaccord Genuity Maintains Buy on Lifetime Brands, Lowers Price Target to $9

<p>Selective Insurance Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIGI#NASDAQ">SIGI</a>) will release its quarterly earnings report on Monday, 2024-10-21. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Selective Insurance Gr to report an <strong>earnings per share</strong> (EPS) of $1.65.</p>
<p>The market awaits Selective Insurance Gr's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Historical Earnings Performance</h3>
<p>Last quarter the company missed EPS by $2.58, which was followed by a 18.18% drop in the share price the next day.</p>
<p>Here's a look at Selective Insurance Gr's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.48</td>
<td>1.84</td>
<td>1.94</td>
<td>1.59</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-1.10</td>
<td>1.33</td>
<td>1.94</td>
<td>1.51</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-18.0%</td>
<td>-6.0%</td>
<td>-8.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729275662_0.png" alt="eps graph" /></p>
<h3>Tracking Selective Insurance Gr's Stock Performance</h3>
<p>Shares of Selective Insurance Gr were trading at $98.89 as of October 17. Over the last 52-week period, shares are down 3.76%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/SIGI/earnings"><strong>To track all earnings releases for Selective Insurance Gr visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


SIGI

Earnings Preview: Selective Insurance Gr

<p>Nucor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>) is gearing up to announce its quarterly earnings on Monday, 2024-10-21. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Nucor will report an <strong>earnings per share</strong> (EPS) of $1.49.</p>
<p>The market awaits Nucor's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Overview of Past Earnings</h3>
<p>During the last quarter, the company reported an EPS beat by $0.33, leading to a 1.1% drop in the share price on the subsequent day.</p>
<p>Here's a look at Nucor's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>2.35</td>
<td>3.65</td>
<td>2.87</td>
<td>4.25</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>2.68</td>
<td>3.46</td>
<td>3.16</td>
<td>4.57</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-1.0%</td>
<td>-9.0%</td>
<td>7.000000000000001%</td>
<td>5.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729275649_0.png" alt="eps graph" /></p>
<h3>Nucor Share Price Analysis</h3>
<p>Shares of Nucor were trading at $158.09 as of October 17. Over the last 52-week period, shares are up 12.94%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analyst Observations about Nucor</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Nucor.</p>
<p>Nucor has received a total of 5 ratings from analysts, with the consensus rating as Outperform. With an average one-year price target of $170.0, the consensus suggests a potential 7.53% upside.</p>
<h3>Comparing Ratings Among Industry Peers</h3>
<p>In this analysis, we delve into the analyst ratings and average 1-year price targets of Steel Dynamics, Reliance and United States Steel, three key industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>The prevailing sentiment among analysts is an Neutral trajectory for Steel Dynamics, with an average 1-year price target of $136.82, implying a potential 13.45% downside.</li>
<li>For Reliance, analysts project an Outperform trajectory, with an average 1-year price target of $325.0, indicating a potential 105.58% upside.</li>
<li>Analysts currently favor an Buy trajectory for United States Steel, with an average 1-year price target of $42.64, suggesting a potential 73.03% downside.</li>
</ul>
<h3>Peer Metrics Summary</h3>
<p>The peer analysis summary provides a snapshot of key metrics for Steel Dynamics, Reliance and United States Steel, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nucor</td>
<td>Outperform</td>
<td>-15.18%</td>
<td>$1.19B</td>
<td>3.10%</td>
</tr>
<tr>
<td>Steel Dynamics</td>
<td>Neutral</td>
<td>-6.28%</td>
<td>$774.84M</td>
<td>3.49%</td>
</tr>
<tr>
<td>Reliance</td>
<td>Outperform</td>
<td>-6.11%</td>
<td>$1.09B</td>
<td>3.44%</td>
</tr>
<tr>
<td>United States Steel</td>
<td>Buy</td>
<td>-17.77%</td>
<td>$489M</td>
<td>1.62%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Nucor ranks highest in gross profit among its peers. However, it ranks lowest in revenue growth and return on equity. Overall, Nucor's performance is mixed compared to its peers.</p>
<h3>About Nucor</h3>
<p>Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products, and raw materials, the steel mills segment derives maximum revenue. The steel mills segment includes carbon and alloy steel in sheet, bars, structural and plate; steel trading businesses; rebar distribution businesses; and Nucor's equity method investments in NuMit and NJSM.</p>
<h3>Nucor: Delving into Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.</p>
<p><strong>Revenue Growth:</strong> Nucor's revenue growth over a period of 3 months has faced challenges. As of 30 June, 2024, the company experienced a revenue decline of approximately <strong>-15.18%</strong>. This indicates a decrease in the company's top-line earnings. When compared to others in the Materials sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>7.95%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Nucor's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>3.1%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>1.89%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> Nucor's debt-to-equity ratio is below the industry average at <strong>0.33</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<p><a href="https://www.benzinga.com/quote/NUE/earnings"><strong>To track all earnings releases for Nucor visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


A Preview Of Nucor's Earnings

<p><strong>Hexcel</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HXL#NYSE">HXL</a>) is set to give its latest quarterly earnings report on Monday, 2024-10-21. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Hexcel will report an <strong>earnings per share</strong> (EPS) of $0.47. </p>
<p>Hexcel bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Historical Earnings Performance</h3>
<p>Last quarter the company beat EPS by $0.04, which was followed by a 0.26% increase in the share price the next day.</p>
<p>Here's a look at Hexcel's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.56</td>
<td>0.41</td>
<td>0.49</td>
<td>0.43</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.60</td>
<td>0.44</td>
<td>0.43</td>
<td>0.38</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>0.0%</td>
<td>2.0%</td>
<td>-8.0%</td>
<td>-8.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729275641_0.png" alt="eps graph" /></p>
<h3>Hexcel Share Price Analysis</h3>
<p>Shares of Hexcel were trading at $62.25 as of October 17. Over the last 52-week period, shares are down 2.7%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<h3>Insights Shared by Analysts on Hexcel</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Hexcel.</p>
<p>Analysts have provided Hexcel with 6 ratings, resulting in a consensus rating of Neutral. The average one-year price target stands at $67.0, suggesting a potential 7.63% upside.</p>
<h3>Comparing Ratings Among Industry Peers</h3>
<p>In this comparison, we explore the analyst ratings and average 1-year price targets of Rocket Lab USA and AeroVironment, three prominent industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Rocket Lab USA is maintaining an Outperform status according to analysts, with an average 1-year price target of $7.12, indicating a potential 88.56% downside.</li>
<li>AeroVironment is maintaining an Outperform status according to analysts, with an average 1-year price target of $224.0, indicating a potential 259.84% upside.</li>
</ul>
<h3>Insights: Peer Analysis</h3>
<p>The peer analysis summary outlines pivotal metrics for Rocket Lab USA and AeroVironment, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hexcel</td>
<td>Neutral</td>
<td>10.15%</td>
<td>$126.60M</td>
<td>3.12%</td>
</tr>
<tr>
<td>Rocket Lab USA</td>
<td>Outperform</td>
<td>71.25%</td>
<td>$27.16M</td>
<td>-8.91%</td>
</tr>
<tr>
<td>AeroVironment</td>
<td>Outperform</td>
<td>24.38%</td>
<td>$81.47M</td>
<td>2.54%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Hexcel ranks highest in gross profit among its peers. It is in the middle for consensus rating and revenue growth. Hexcel is at the bottom for return on equity.</p>
<h3>Discovering Hexcel: A Closer Look</h3>
<p>Founded in 1948, Hexcel designs and manufactures a range of highly engineered composite fibers, fabrics, resins, and structures for use in commercial aerospace, defense, and other industrial markets. These are lighter than metal and perform under rigorous conditions in aircraft frames, wings, engines, and other components and subassemblies. The company's name derives from the six-sided honeycomb structures that lend many of its products their light weight and rigidity. Hexcel's biggest customers are Airbus (38% of 2022 sales) and Boeing (25% of prepandemic sales) and its respective subcontractors.</p>
<h3>Hexcel: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Hexcel's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of <strong>10.15%</strong>. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Industrials sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Hexcel's net margin excels beyond industry benchmarks, reaching <strong>9.99%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Hexcel's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>3.12%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Hexcel's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>1.77%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Hexcel's debt-to-equity ratio is below the industry average at <strong>0.51</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<p><a href="https://www.benzinga.com/quote/HXL/earnings"><strong>To track all earnings releases for Hexcel visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Hexcel Earnings Preview

<p>Wintrust Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTFC#NASDAQ">WTFC</a>) is preparing to release its quarterly earnings on Monday, 2024-10-21. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Wintrust Finl to report an <strong>earnings per share</strong> (EPS) of $2.51.</p>
<p>Investors in Wintrust Finl are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Overview of Past Earnings</h3>
<p>The company's EPS missed by $0.10 in the last quarter, leading to a 4.98% drop in the share price on the following day.</p>
<p>Here's a look at Wintrust Finl's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>2.42</td>
<td>2.42</td>
<td>2.49</td>
<td>2.41</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>2.32</td>
<td>2.89</td>
<td>2.40</td>
<td>2.53</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-5.0%</td>
<td>0.0%</td>
<td>3.0%</td>
<td>0.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729275633_0.png" alt="eps graph" /></p>
<h3>Tracking Wintrust Finl's Stock Performance</h3>
<p>Shares of Wintrust Finl were trading at $117.01 as of October 17. Over the last 52-week period, shares are up 56.54%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/WTFC/earnings"><strong>To track all earnings releases for Wintrust Finl visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


WTFC

Insights Ahead: Wintrust Finl's Quarterly Earnings

<p>Enterprise Finl Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EFSC#NASDAQ">EFSC</a>) is gearing up to announce its quarterly earnings on Monday, 2024-10-21. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Enterprise Finl Servs will report an <strong>earnings per share</strong> (EPS) of $1.14.</p>
<p>Investors in Enterprise Finl Servs are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Historical Earnings Performance</h3>
<p>Last quarter the company beat EPS by $0.15, which was followed by a 12.37% increase in the share price the next day.</p>
<p>Here's a look at Enterprise Finl Servs's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.06</td>
<td>1.11</td>
<td>1.19</td>
<td>1.24</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.21</td>
<td>1.07</td>
<td>1.21</td>
<td>1.17</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>12.0%</td>
<td>-1.0%</td>
<td>-4.0%</td>
<td>-6.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729275625_0.png" alt="eps graph" /></p>
<h3>Enterprise Finl Servs Share Price Analysis</h3>
<p>Shares of Enterprise Finl Servs were trading at $53.85 as of October 17. Over the last 52-week period, shares are up 48.98%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/EFSC/earnings"><strong>To track all earnings releases for Enterprise Finl Servs visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


<p>Medpace Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDP#NASDAQ">MEDP</a>) will release its quarterly earnings report on Monday, 2024-10-21. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Medpace Hldgs to report an <strong>earnings per share</strong> (EPS) of $2.80.</p>
<p>Investors in Medpace Hldgs are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Earnings Track Record</h3>
<p>The company's EPS beat by $0.21 in the last quarter, leading to a 18.27% drop in the share price on the following day.</p>
<p>Here's a look at Medpace Hldgs's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>2.54</td>
<td>2.46</td>
<td>2.22</td>
<td>2.04</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>2.75</td>
<td>3.20</td>
<td>2.46</td>
<td>2.22</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-18.0%</td>
<td>8.0%</td>
<td>12.0%</td>
<td>20.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729275625_0_0.png" alt="eps graph" /></p>
<h3>Medpace Hldgs Share Price Analysis</h3>
<p>Shares of Medpace Hldgs were trading at $342.89 as of October 17. Over the last 52-week period, shares are up 55.53%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analyst Insights on Medpace Hldgs</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Medpace Hldgs.</p>
<p>With 10 analyst ratings, Medpace Hldgs has a consensus rating of Neutral. The average one-year price target is $395.6, indicating a potential 15.37% upside.</p>
<h3>Comparing Ratings with Peers</h3>
<p>In this comparison, we explore the analyst ratings and average 1-year price targets of Bio-Techne, Charles River and Bio-Rad Laboratories, three prominent industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>The prevailing sentiment among analysts is an Buy trajectory for Bio-Techne, with an average 1-year price target of $82.33, implying a potential 75.99% downside.</li>
<li>Charles River received a Neutral consensus from analysts, with an average 1-year price target of $203.75, implying a potential 40.58% downside.</li>
<li>The consensus outlook from analysts is an Neutral trajectory for Bio-Rad Laboratories, with an average 1-year price target of $378.4, indicating a potential 10.36% upside.</li>
</ul>
<h3>Peers Comparative Analysis Summary</h3>
<p>The peer analysis summary provides a snapshot of key metrics for Bio-Techne, Charles River and Bio-Rad Laboratories, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medpace Hldgs</td>
<td>Neutral</td>
<td>14.59%</td>
<td>$153.84M</td>
<td>12.31%</td>
</tr>
<tr>
<td>Bio-Techne</td>
<td>Buy</td>
<td>1.59%</td>
<td>$203.35M</td>
<td>1.99%</td>
</tr>
<tr>
<td>Charles River</td>
<td>Neutral</td>
<td>-3.19%</td>
<td>$353.71M</td>
<td>2.44%</td>
</tr>
<tr>
<td>Bio-Rad Laboratories</td>
<td>Neutral</td>
<td>-6.26%</td>
<td>$355.12M</td>
<td>-27.36%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Medpace Hldgs ranks in the middle among its peers for revenue growth, with positive growth compared to some peers. It is at the top for gross profit, indicating strong profitability. However, its return on equity is lower than some peers, suggesting room for improvement in utilizing shareholder equity effectively. Overall, Medpace Hldgs shows a balanced performance compared to its peers in these key financial metrics.</p>
<h3>All You Need to Know About Medpace Hldgs</h3>
<p>Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical-device firms. It also offers ancillary services such as bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has over 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati and its operations are principally based in the us, but it also operates in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.</p>
<h3>Unraveling the Financial Story of Medpace Hldgs</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Medpace Hldgs showcased positive performance, achieving a revenue growth rate of <strong>14.59%</strong> as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Medpace Hldgs's net margin is impressive, surpassing industry averages. With a net margin of <strong>16.73%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Medpace Hldgs's ROE excels beyond industry benchmarks, reaching <strong>12.31%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Medpace Hldgs's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>4.76%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> Medpace Hldgs's debt-to-equity ratio is below the industry average. With a ratio of <b>0.17</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<p><a href="https://www.benzinga.com/quote/MEDP/earnings"><strong>To track all earnings releases for Medpace Hldgs visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Exploring Medpace Hldgs's Earnings Expectations

<p>WR Berkley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WRB#NYSE">WRB</a>) is gearing up to announce its quarterly earnings on Monday, 2024-10-21. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that WR Berkley will report an <strong>earnings per share</strong> (EPS) of $0.95.</p>
<p>The market awaits WR Berkley's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Historical Earnings Performance</h3>
<p>In the previous earnings release, the company beat EPS by $0.12, leading to a 0.75% increase in the share price the following trading session.</p>
<p>Here's a look at WR Berkley's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.92</td>
<td>0.96</td>
<td>0.92</td>
<td>0.79</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.04</td>
<td>1.04</td>
<td>0.97</td>
<td>0.90</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>1.0%</td>
<td>-2.0%</td>
<td>7.000000000000001%</td>
<td>6.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729275616_0.png" alt="eps graph" /></p>
<h3>Market Performance of WR Berkley's Stock</h3>
<p>Shares of WR Berkley were trading at $61.04 as of October 17. Over the last 52-week period, shares are up 46.33%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/WRB/earnings"><strong>To track all earnings releases for WR Berkley visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Exploring WR Berkley's Earnings Expectations

<p>Alexandria Real Estate (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARE#NYSE">ARE</a>) will release its quarterly earnings report on Monday, 2024-10-21. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Alexandria Real Estate to report an <strong>earnings per share</strong> (EPS) of $2.37.</p>
<p>Alexandria Real Estate bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Earnings History Snapshot</h3>
<p>The company's EPS beat by $0.02 in the last quarter, leading to a 3.52% drop in the share price on the following day.</p>
<p>Here's a look at Alexandria Real Estate's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>2.34</td>
<td>2.32</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>2.36</td>
<td>2.35</td>
<td>2.28</td>
<td>2.26</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-4.0%</td>
<td>1.0%</td>
<td>-4.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>
</p>
<h3>Stock Performance</h3>
<p>Shares of Alexandria Real Estate were trading at $121.25 as of October 17. Over the last 52-week period, shares are up 29.0%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analyst Views on Alexandria Real Estate</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Alexandria Real Estate.</p>
<p>A total of 8 analyst ratings have been received for Alexandria Real Estate, with the consensus rating being Neutral. The average one-year price target stands at $128.88, suggesting a potential 6.29% upside.</p>
<h3>Analyzing Ratings Among Peers</h3>
<p>The following analysis focuses on the analyst ratings and average 1-year price targets of Ventas, Healthpeak Properties and Omega Healthcare Invts, three prominent industry players, providing insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Outperform trajectory for Ventas, with an average 1-year price target of $65.88, suggesting a potential 45.67% downside.</li>
<li>As per analysts' assessments, Healthpeak Properties is favoring an Outperform trajectory, with an average 1-year price target of $24.29, suggesting a potential 79.97% downside.</li>
<li>Omega Healthcare Invts received a Neutral consensus from analysts, with an average 1-year price target of $42.2, implying a potential 65.2% downside.</li>
</ul>
<h3>Summary of Peers Analysis</h3>
<p>The peer analysis summary outlines pivotal metrics for Ventas, Healthpeak Properties and Omega Healthcare Invts, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alexandria Real Estate</td>
<td>Neutral</td>
<td>7.40%</td>
<td>$549.48M</td>
<td>0.23%</td>
</tr>
<tr>
<td>Ventas</td>
<td>Outperform</td>
<td>8.55%</td>
<td>$519.18M</td>
<td>0.20%</td>
</tr>
<tr>
<td>Healthpeak Properties</td>
<td>Outperform</td>
<td>27.31%</td>
<td>$413.85M</td>
<td>1.65%</td>
</tr>
<tr>
<td>Omega Healthcare Invts</td>
<td>Neutral</td>
<td>1.02%</td>
<td>$249.00M</td>
<td>3.15%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Alexandria Real Estate ranks in the middle for revenue growth among its peers. It is at the bottom for gross profit and return on equity.</p>
<h3>About Alexandria Real Estate</h3>
<p>Alexandria Real Estate Equities Inc is an urban office real estate investment trust (REIT). It is engaged in the business of providing space for lease to life science, agtech, and technology tenants. The company has established a significant market presence in key locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. Alexandria has a longstanding and proven track record of developing Class A properties clustered in urban life science, agtech, and technology campuses that provide tenants with highly dynamic and collaborative environments. Alexandria also provides strategic capital to transformative life science, agtech, and technology companies through venture capital platform.</p>
<h3>Financial Insights: Alexandria Real Estate</h3>
<p><strong>Market Capitalization:</strong> Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Alexandria Real Estate showcased positive performance, achieving a revenue growth rate of <strong>7.4%</strong> as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Real Estate sector.</p>
<p><strong>Net Margin:</strong> Alexandria Real Estate's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>5.6%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Alexandria Real Estate's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>0.23%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Alexandria Real Estate's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>0.11%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Alexandria Real Estate's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.7</strong>.</p>
<p><a href="https://www.benzinga.com/quote/ARE/earnings"><strong>To track all earnings releases for Alexandria Real Estate visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


A Preview Of Alexandria Real Estate's Earnings

<p>Guaranty Bancshares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNTY#NYSE">GNTY</a>) will release its quarterly earnings report on Monday, 2024-10-21. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Guaranty Bancshares to report an <strong>earnings per share</strong> (EPS) of $0.60.</p>
<p>The market awaits Guaranty Bancshares's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Earnings Track Record</h3>
<p>The company's EPS beat by $0.11 in the last quarter, leading to a 4.17% increase in the share price on the following day.</p>
<p>Here's a look at Guaranty Bancshares's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.54</td>
<td>0.51</td>
<td>0.47</td>
<td>0.55</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.65</td>
<td>0.58</td>
<td>0.51</td>
<td>0.54</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>4.0%</td>
<td>-4.0%</td>
<td>-0.0%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729275597_0.png" alt="eps graph" /></p>
<h3>Performance of Guaranty Bancshares Shares</h3>
<p>Shares of Guaranty Bancshares were trading at $35.58 as of October 17. Over the last 52-week period, shares are up 29.53%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/GNTY/earnings"><strong>To track all earnings releases for Guaranty Bancshares visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Comments

Earth Life Sciences

Notizie

Ultime notizie per Earth Life Sciences (OTC:CLTS) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO